These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35832757)

  • 1. Clinical Profile and the Extent of Disability in Multiple Sclerosis Patients in Madinah, Saudi Arabia.
    Alsaedi EQ; Alsaedi MQ; Mansuri FA
    Cureus; 2022 Jun; 14(6):e25851. PubMed ID: 35832757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
    Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
    Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Exercise on Fatigue Among Patients With Multiple Sclerosis in the King Fahad Hospital, Madinah, Saudi Arabia: An Analytical Cross-Sectional Study.
    Alsharif ZI; Mansuri FA; Alamri YA; Alkalbi NA; Almutairi MM; Abu Alkhair AF
    Cureus; 2023 Jul; 15(7):e42061. PubMed ID: 37601996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden.
    Beiki O; Frumento P; Bottai M; Manouchehrinia A; Hillert J
    JAMA Neurol; 2019 Jun; 76(6):665-671. PubMed ID: 30882868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Prevalence of Comorbidities Associated with Multiple Sclerosis in Saudi Arabia.
    Alnajashi H; Wali A; Aqeeli A; Magboul A; Alfulayt M; Baasher A; Alzahrani S
    Ann Afr Med; 2024 Oct; 23(4):600-605. PubMed ID: 39138964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No evidence of disease activity-3 (NEDA-3) status in patients with relapsing remitting multiple sclerosis: Evidence from Saudi cohort receiving mainly Interferon.
    Zafar A; AlShamrani FJG
    Mult Scler Relat Disord; 2021 Jun; 51():102875. PubMed ID: 33691260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone.
    Foo EC; Russell M; Lily O; Ford HL
    Mult Scler Relat Disord; 2020 Sep; 44():102330. PubMed ID: 32599468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of oral agents in relapsing-remitting multiple sclerosis compared to interferon-based therapy in Saudi Arabia.
    Alsaqa'aby MF; Vaidya V; Khreis N; Khairallah TA; Al-Jedai AH
    Ann Saudi Med; 2017; 37(6):433-443. PubMed ID: 29229891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential disease phenotypes and progression in relapsing-remitting multiple sclerosis: comparative analyses of single Canadian and Saudi Arabian clinics.
    Alluqmani M; Roda W; Qqrmli M; Blevins G; Giuliani F; Power C
    BMC Neurol; 2021 Jul; 21(1):295. PubMed ID: 34311734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Characteristics and Disability Progression of Early- and Late-Onset Multiple Sclerosis Compared to Adult-Onset Multiple Sclerosis.
    Mirmosayyeb O; Brand S; Barzegar M; Afshari-Safavi A; Nehzat N; Shaygannejad V; Sadeghi Bahmani D
    J Clin Med; 2020 May; 9(5):. PubMed ID: 32370288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discontinuation of disease modifying therapies is associated with disability progression regardless of prior stable disease and age.
    Jakimovski D; Kavak KS; Vaughn CB; Goodman AD; Coyle PK; Krupp L; Gottesman M; Edwards KR; Lenihan M; Perel A; Zivadinov R; Weinstock-Guttman B;
    Mult Scler Relat Disord; 2022 Jan; 57():103406. PubMed ID: 34915316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilization of the multiple sclerosis functional composite in follow-up: relationship to disease phenotype, disability and treatment strategies.
    Ozakbas S; Ormeci B; Idiman E
    J Neurol Sci; 2005 May; 232(1-2):65-9. PubMed ID: 15850584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fingolimod for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia.
    Algahtani H; Shirah B; Al Malik Y; Meftah I
    Clin Neuropharmacol; 2020; 43(2):35-38. PubMed ID: 32106137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
    Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
    Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab for relapsing-remitting multiple sclerosis.
    He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of glatiramer acetate (Copaxone) and interferon beta-1b (Betaferon) in multiple sclerosis patients: an open-label 2-year follow-up.
    Flechter S; Vardi J; Pollak L; Rabey JM
    J Neurol Sci; 2002 May; 197(1-2):51-5. PubMed ID: 11997066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-fat, plant-based diet in multiple sclerosis: A randomized controlled trial.
    Yadav V; Marracci G; Kim E; Spain R; Cameron M; Overs S; Riddehough A; Li DK; McDougall J; Lovera J; Murchison C; Bourdette D
    Mult Scler Relat Disord; 2016 Sep; 9():80-90. PubMed ID: 27645350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the outcome of multiple sclerosis among Saudi adult patients. A single-centered cross-sectional study at King Abdulaziz Medical City in Riyadh, Saudi Arabia.
    Alanazi AM; Al-Rashoud JR; Aljahani JM; Alotaibi AF; Althubaiti AM; Kojan SM; Aljumah MA; Abulaban AA
    Neurosciences (Riyadh); 2019 Jul; 24(3):168-175. PubMed ID: 31380815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study.
    Kopp TI; Blinkenberg M; Petersen T; Sorensen PS; Magyari M
    Mult Scler Relat Disord; 2020 May; 40():101956. PubMed ID: 32007654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.